acceptance

Soft Space Enters into Strategic Partnership with JCB

  Collaboration will expand JCB's presence in Southeast Asia and act as a bridge for Soft Space to link Japanese consumers with the region and vice versa KUALA LUMPUR & TOKYO, Jan 13, 2022 - (JCN Newswire) - The world's leading fintech player, Soft Space Sdn. Bhd. ("Soft Space"), has announced a new strategic partnership with Japan's only international payment brand, JCB Co. Ltd. ("JCB"). This strategic partnership is the first of its kind in Malaysia for the payment giant and involves a combination of US$5 million investment in Soft

Crypto Payments Come to Adelaide Oval via Crypto.com

First-Ever Crypto Payment Integration for Major Stadium in Australia VIDEOS AND IMAGES AVAILABLE IN LINK BELOW Adelaide, April 4, 2024 - Crypto.com, trusted by more than 80 million customers worldwide and the industry leader in regulatory compliance, security and privacy, announced today that sports fans and concert-goers can now pay via Crypto.com Pay, Crypto.com’s payment solution, at Adelaide Oval, the home of the Adelaide Crows. Supported by Adelaide Oval, Adelaide Crows and financial systems software firm DataMesh, which is providing the payment technology and terminals, this integration will mark a

The Convergence of MedTech and Blockchain: Transforming Healthcare

The healthcare industry has witnessed a remarkable transformation driven by technological advancements in recent years. One groundbreaking convergence is the fusion of Medical Technology (MedTech) and blockchain technology. This synergy has the potential to revolutionize healthcare by enhancing data security, interoperability, and patient-centric care. Enhanced Data Security: One of the foremost challenges in healthcare is ensuring the security and privacy of patient data. Medical records contain sensitive information that must be protected from unauthorized access and cyber threats. Blockchain technology offers a robust solution to this problem. Blockchain operates on

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating